Merck & Co., Inc. (NYSE:MRK) has recently caught the attention of analysts, with Deutsche Bank upgrading the stock to a 'Buy' from 'Hold' on February 13. Analyst James Shin raised the price target from $115 to $150, stating that the market is undervaluing Merck due to worries surrounding the upcoming patent expiration of Keytruda.
Shin emphasized a 'clear path' for Merck to navigate this transition, pointing out that the company possesses visible growth drivers beyond Keytruda. He mentioned that Merck is currently experiencing a trough earnings formation, indicating potential for recovery and growth.
Despite this optimistic outlook, Merck's recent forecast for 2026 fell short of Wall Street expectations. On February 3, the company announced projected revenue between $65.5 billion and $67.0 billion, which is below the average analyst estimate of $67.6 billion according to LSEG data. Merck anticipates a $2.5 billion headwind this year, primarily due to generic competition, Medicare price negotiations, and declining sales of its COVID-19 treatment, Lagevrio.
During an interview, CEO Rob Davis explained the disconnect between the company's performance and street expectations, attributing it to legacy products losing patent protection. He noted that drugs like Januvia, alongside treatments such as Janumet and Janumet XR, may perform below analyst projections as they approach the end of their exclusivity period.
Merck & Co., Inc. operates as a global healthcare leader, focusing on the development and delivery of prescription medicines, vaccines, and animal health products. The pharmaceutical segment is dedicated to human health treatments and vaccines.
While Merck shows considerable investment potential, some analysts suggest that certain AI stocks present greater upside potential with less downside risk. For those looking for undervalued AI stocks that may gain from recent economic trends, including tariff impacts and onshoring, a free report on the best short-term AI stock is available.